drugset / Trial / NCT04645069
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
Timeline
- Start
- 2021-03-15
- Primary completion
- 2024-01-29
- Completion
- 2024-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADG106 | Monoclonal antibody | — | — |
| Subject | Muzastotug | Monoclonal antibody | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | — |
Indications
No indication recorded.